Document is current
Any future updates will be listed below
-
Authors
Kroupova, Alena https://orcid.org/0000-0003-4166-1270
Spiteri, Valentina A.
Rutter, Zoe J.
Furihata, Hirotake
Darren, Darren https://orcid.org/0009-0007-7012-3486
Ramachandran, Sarath https://orcid.org/0000-0002-0922-9448
Chakraborti, Sohini https://orcid.org/0000-0002-4591-2658
Haubrich, Kevin https://orcid.org/0000-0001-5025-3821
Pethe, Julie
Gonzales, Denzel
Wijaya, Andre J.
Rodriguez-Rios, Maria https://orcid.org/0000-0003-2434-1603
Sturbaut, Manon https://orcid.org/0000-0002-4026-2211
Lynch, Dylan M. https://orcid.org/0000-0001-6245-9704
Farnaby, William https://orcid.org/0000-0001-8610-932X
Nakasone, Mark A. https://orcid.org/0000-0002-1362-191X
Zollman, David https://orcid.org/0000-0002-7613-2013
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 19 September 2024
First Online: 15 October 2024
Competing interests
: The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. AC is a scientific founder and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The remaining authors declare no competing interests.
